Cixutumumab

Cixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding downstream signaling. Additionally, it facilitates the internalization and degradation of IGF-1R. Demonstrating extensive antitumor efficacy, it is relevant in cancer research, including lung and prostate cancers, malignancies, and leukemia .